Status:
COMPLETED
FOLFOX Followed by FOLFIRI or Reverse Sequence Treatment in Advanced Gastric Cancer (AGC)
Lead Sponsor:
Dong-A University Hospital
Collaborating Sponsors:
Pusan National University Yangsan Hospital
Conditions:
Gastric Cancer
Eligibility:
All Genders
20+ years
Phase:
PHASE2
Brief Summary
FOLFOX\* followed by FOLFIRI\*\* or reverse sequence treatment regimen have been used as a standard treatment modality in metastatic colorectal cancer.Oxaliplatin and Irinotecan were used for advanced...
Detailed Description
Gastric cancer remains a major public health issue, and is the fourth most common cancer and the second leading cause of cancer deaths worldwide. In Korea, gastric cancer is the most common cancer in ...
Eligibility Criteria
Inclusion
- Histologically confirmed gastric cancer
- No prior chemotherapy for palliative setting
- ECOG PS \<3
- Measurable lesion on CT
- adequate kidney function (CCr ≥ 40 ml/min)
- adequate liver function (Transaminase \< 3 X upper normal value, Bilirubin \< 2 mg%)
- adequate BM function (ANC \> 1500/ul, platelet \> 75000/ul)
- informed consent
Exclusion
- other cancer history
- pregnant or breast feeding
- inadequate general condition for chemotherapy
- allergy to oxaliplatin or irinotecan
Key Trial Info
Start Date :
September 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 1 2013
Estimated Enrollment :
80 Patients enrolled
Trial Details
Trial ID
NCT01138904
Start Date
September 1 2009
End Date
September 1 2013
Last Update
November 4 2014
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Sung Yong Oh
Busan, South Korea, 602-715